Nanovibronix Inc Stock Price, News & Analysis

NanoVibronix, Inc. (NASDAQ: NAOV) reported significant growth in its third quarter 2021, with revenues of $499,000, a 233% increase year-over-year. The company introduced a new CBD gel for pain management and expanded into the workers' compensation market. A backlog of orders exceeds $600,000, indicating strong sales momentum. Despite a net loss of $6.7 million, the balance sheet remains robust with $8.6 million in cash and no long-term debt. Future catalysts include new product launches and expanding markets.

NanoVibronix, Inc. (NASDAQ: NAOV) reported significant developments in its business update on October 28, 2021. Key highlights include the successful introduction of new products, PainShield Plus and PainShield Relief, along with advancements in reimbursement efforts for the PainShield™ product, which now has a dedicated Medicare code. Despite ongoing supply chain challenges, the company expects to fulfill order backlogs by Q4 2021. Clinical studies have shown high effectiveness for PainShield™, with a 92% success rate in treating Tennis Elbow. Financially, NanoVibronix maintains a robust balance sheet with $8.6 million in cash and no debt.

NanoVibronix (NASDAQ: NAOV) announced promising results from a study on its PainShield device for treating tennis elbow (lateral epicondylitis). Conducted at Birmingham Orthopedic and Sports Specialists, the randomized trial showed that 91% of patients experienced complete or partial symptom resolution after using PainShield, along with over-the-counter medications. The device proved safe and effective, requiring no opioids. CEO Brian Murphy emphasized its ease of use and efficacy, while Lead Investigator Dr. David Lemak noted significant patient outcomes without prescription medications.

NanoVibronix, Inc. (NASDAQ: NAOV) has signed a Provider Participation Agreement with Orchid Medical, enhancing access to its PainShield® product for workers' compensation beneficiaries. This partnership marks NanoVibronix's entry into the workers' compensation market, streamlining reimbursement for eligible patients. Under the two-year agreement, the company will provide initial supply kits at a fixed price, with annual renewals. PainShield is designed for pain management and is suitable for home or clinical use, offering benefits such as faster recovery times and increased safety.

NanoVibronix (NASDAQ: NAOV) has announced the launch of a new CBD gel designed for the topical treatment of pain and inflammation. This product aims to expand the market for NanoVibronix's PainShield line, providing an additional revenue stream. The gel features nano-cannabidiol sourced from High Purity Natural Products, an FDA-registered manufacturer. The company anticipates product availability by mid-2022, positioning it as a complementary option for common ailments like arthritis, while still maintaining the efficacy of existing pain management devices.

NanoVibronix, Inc (NASDAQ: NAOV) held its Annual Meeting of Stockholders virtually. Key resolutions adopted include the election of six director nominees, an amendment to increase the number of authorized shares, the ratification of Marcum LLP as independent auditor, and advisory approvals for executive compensation.

The company focuses on medical devices like UroShield® and PainShield®, utilizing patented low-intensity surface acoustic wave (SAW) technology, aiming for applications in pain relief and biofilm disruption.

NanoVibronix, Inc. (NASDAQ: NAOV) announces its entry into the Over-the-Counter (OTC) pain relief market with the launch of PainShield RELIEF™, a non-prescription ultrasound device aimed at providing rapid pain relief for soft tissue and nerve damage. CEO Brian Murphy notes this significant market expansion opens new revenue opportunities for the company. Plans are in place for a U.S. launch and trade show reveals in early to mid-2022. The company is also preparing to submit a regulatory application to the FDA and protect its trademark.

NanoVibronix, Inc. (NASDAQ: NAOV) has secured regulatory approval from Australia's TGA for its PainShield device, following the recent approval of UroShield. This allows for distribution in Australia through their new partnership with DukeHill Healthcare Pty Ltd, enhancing access to their ultrasound-based therapeutic devices. PainShield offers treatment for acute and chronic pain, while UroShield aims to reduce urinary catheter infection risks. The strategic partnership positions NanoVibronix to effectively meet market demands in Australia.

NanoVibronix, Inc. (NASDAQ: NAOV) announced it completed the application process for a CMS reimbursement code for its UroShield and PainShield Plus devices. CEO Brian Murphy stated this initiative aims to significantly expand the market for these therapies, particularly among Medicare beneficiaries. The UroShield is designed to prevent urinary tract infections, while PainShield Plus provides ultrasound therapy for pain treatment at home. Approval of the reimbursement code is seen as a catalyst for increasing revenue opportunities for the company.